Editorial educational content. Specialist review is not claimed; consult the original references and limitations.
One sequence, several properties
An amino acid is a chemical building block; a peptide contains building blocks connected in a particular order. That order matters: chains with similar compositions can have different properties. Proteins are also made of amino acids, but their description usually involves larger chains, three-dimensional organization and complex functions. A single numerical cutoff does not settle every naming question.
Start with molecular identity: name, sequence when available, modifications and chemical form. Then examine the commercial variant. “10 mg per vial” describes nominal quantity; it does not establish purity, actual content, solution concentration or an analytical result.
Identity is not a packaging variant
A compound may be supplied in different quantities, salts or formats. Some differences go beyond packaging: a covalent modification, fragment or different sequence can change the identity that must be searched in the literature. Names with DAC and without DAC, for example, should not be treated as interchangeable synonyms by a search algorithm.
Ask three separate questions: which chemical entity is requested; which specification was agreed; and what evidence accompanies the delivered batch? A product-card name only partly answers the first. Compare codes, documents and nomenclature before connecting a study to a material.
Mass, content and concentration
A box containing ten 10 mg vials contains a nominal 100 mg. This is not 100 mg/mL: the solution volume is missing. Nominal content also does not replace an analytical determination of assay. For blends, retain each component's identity; adding masses does not turn different substances into one entity.
| Information | Question answered |
|---|---|
| Identity | Which compound or sequence is described? |
| Mass per vial | What nominal quantity accompanies one unit? |
| Packaging | How many units make up the box? |
| Batch analysis | What was measured, by which method and with what result? |
Continue your reading
The Wang review provides context on therapeutic-peptide production and modification. The Xiao review discusses delivery platforms and development. These publications address research and medicinal products; they do not establish the quality of a product in this catalog.
Use monographs to explore identities and the glossary for analytical terminology. For a quotation, specify the variant and required documents. A clearly defined chemical question helps avoid comparing materials that have similar names but do not address the same experimental objective.
Sources and verification scope
Therapeutic peptides: current applications and future directions ↗
Wang et al. · Signal Transduction and Targeted Therapy
Source details (original language)
- Scope
- Review of therapeutic peptide development
- Document section
- Introduction; production, modification and applications
- Limitations
- Historical review, not validation of products or batches. More than 80 approved drugs is a 2022 literature statement.
- Claim verification date
- 2026-09-09
Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines ↗
Xiao et al. · Signal Transduction and Targeted Therapy
Source details (original language)
- Scope
- Historical review reporting 28 approvals in 2014–2024 and 38 phase III candidates
- Document section
- Peptide-based drug market & clinical trial; Figure 4 and Tables 2–3
- Limitations
- Denominators differ between narrative and tables; no new percentages or current regulatory count inferred.
- Claim verification date
- 2026-09-09
Related commercial identities
Related research concerns the compound; it does not establish use of our product or lot in the study.
Related reading
Reading peptide documentation: identity, purity, content and COA
How to distinguish specifications, batch results, assay and microbiological attributes.
Read details →